Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Webinars
AUANewsWorthy Webinars
Introducing an exciting and informative sponsored webinar series: AUANewsWorthy Webinars. In collaboration with industry leaders, we are proud to present a series of thought-provoking webinars designed to empower professionals in what's new in the field of urology. Whether you’re a practice manager, resident, young urologist, or a seasoned urologist, these webinars offer a unique opportunity to explore the latest topics, strategies, and advancements shaping urology today.
August 2023
Stream this two-part AUANewsWorthy Webinar series featuring members of the AUA’s Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO 2023 Guideline Panel.
November 2023
Join Dr. Moul and Dr. Morris as they discuss apalutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer. Through discussion of patient case studies, this webinar will highlight key data from the Phase 3 TITAN study and review the efficacy and safety data of apalutamide with ADT. Dr.'s Moul and Morris will also delve into subpopulation analyses and prostate-specific antigen kinetics from the TITAN study.
December 2023
The 4-part AUANewsWorthy webinar roundtable series focuses on breaking news in bladder cancer advancements with insights from top urology experts. This non-CME bladder cancer roundtable webinar series offers a unique opportunity to highlight the latest bladder cancer treatment trends from the top experts in the field.
January 2024
Historically, the standard of care for muscle invasive urothelial carcinoma (MIUC) was radical surgery with cisplatin-based chemotherapy in eligible populations; however, more than 50% of patients still have a metastatic progression following radical surgery. This non-CME webinar focuses on the opportunity to highlight the need for additional treatments in patients with UC post-radical resection.
February 2024
AUANews Patient Editor Tom Hulsey interviews Dr. Sandip M. Prasad about the recently published findings of The Atlas Group in The Journal of Urology®. This interview focuses on important insights from Dr. Prasad, including study need and importance, what the authors found, study limitations, interpretations for patient care, and more.
March 2024
Join Patient Editor Tom Hulsey as he continues his conversation with Dr. Sandip M. Prasad and two bladder cancer patients. Donald McNally was an ATLAS patient and discusses his experience and outcomes thus far with the trial. John Rybka, a member of the Bladder Cancer Advocacy Network, shares his perspective on the importance of this research and the potential for how bladder cancer is treated in the future.
May 2024
The webinar covers the background of molecular imaging and PSMA-PET and discusses both OSPREY and CONDOR study designs and topline results. Dr. Rowe shares and discusses interesting case studies from his over 3 years’ experience using PSMA-targeted PET imaging to demonstrate the role of PSMA-PET in informing treatment decisions both at the initial staging of men with high risk disease, as well as in the recurrent setting as well as discussing the prognostic value of PSMA-PET.
July 2024
Partnering with Patients for the Pharmacological Management of Overactive Bladder
October 2024
The presentation focuses on Gallium 68-PSMA-11 (Illuccix) PET/CT imaging for Initial Staging of Prostate Cancer, Biochemical Recurrence and for the selection of patients for whom Lu177-PSMA-617 is indicated.
November 2024
A discussion on the role of a novel treatment in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). We will consider the challenges of treating BCG-unresponsive high-risk NMIBC, understand the durability, dosing, and safety profile, as well as review practical considerations for incorporating novel treatment into your clinic.
AUANews Webinars
AUANews is pleased to offer free webinars as a benefit to the global urological community. These events are designed to keep you updated on the latest AUA member and clinical news, including how to get involved in all aspects of the AUA, including submitting a successful Annual Meeting abstract, public advocacy and policy involvement opportunities, and more. Led by AUA members for AUA members, these webinars are a great way for members of all career stages to learn more about urology and the AUA.
October 2023
Each year, the AUA Annual Meeting receives thousands of scientific abstracts for its Annual Meeting. Of those, approximately 1/3 are selected for presentation. Join us for a live virtual event where AUA leaders will provide a behind-the-scenes look at the abstract process and provide insights and strategies to submit a selected abstract.
November 2023
Dr Rena Malik interviews Melissa Assel, Chief Statistician of The Journal of Urology®, about JU’s rigorous statistical review process. Whether you’re a first-time submitter or a seasoned author, this informative webinar provides a transparent view into the importance of statistical presentation in the peer review process.
May 2024
Ruchika Talwar, MD, joined the AUA to discuss a career path in Urology and Health Policy.
April 2024
With the launch of our 4th annual Diversity focus issue, Dr. Stacy Tanaka (Editor-in-Chief), Dr. John Denstedt (former Editor-in Chief and current Global Urology Editor) and Dr. Tracy Downs (Inaugural Diversity Issue Guest Editor) take time to reflect on the history, importance, and future of this important AUANews focus issue.
May 2024
Treatment options in muscle invasive urothelial carcinoma (MIUC) and metastatic urothelial carcinoma (mUC) have evolved in recent years.